NeON gets new head, as IPG bumps Lane upstairs

Share this article:
Mark Arnold
Mark Arnold

Interpublic Group promoted Matt Lane, co-founder and managing director of NeON, to a position at the holding company level. The agency's parent company, Draftfcb Healthcare, immediately named his successor.

Taking Lane's place at NeON is new managing director Mark Arnold, formerly SVP, managing supervisor at Omnicom's AgencyRx, said Dana Maiman, CEO of Draftfcb Healthcare. Before coming to AgencyRx, Arnold had been with Euro RSCG Life.

Arnold now joins NeON EVP, executive creative director Kevin McHale, who was brought on from Euro RSCG to lead creative in December.

In his new role, Lane will aid IPG with healthcare holding company consolidations, a new position. The network has been a beneficiary of the last three Big Pharma advertising business reviews: Merck's this past May, GlaxoSmithKline's in late 2010, and Johnson & Johnson's in 2008.

One of two Draftfcb Healthcare conflict shops, NeON services about 40 brand assignments from Pfizer, Boehringer Ingelheim and Gilead, with 100 employees working on digital promotion and traditional advertising as well as consulting.

Lane helped launch the agency in 2009 with a pair of brands from the roster of sister agency Area 23, where he had also been a managing director. He started his first agency after stints as a Pfizer sales rep and account manager at CDM.

Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Channel

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...